이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lisata Therapeutics 관리

관리 기준 확인 3/4

Lisata Therapeutics' CEO는 Dave Mazzo, Jan2015 에 임명되었습니다 의 임기는 9.42 년입니다. 총 연간 보상은 $ 1.41M, 48% 로 구성됩니다. 48% 급여 및 52% 보너스(회사 주식 및 옵션 포함). 는 $ 576.73K 가치에 해당하는 회사 주식의 2.1% 직접 소유합니다. 576.73K. 경영진과 이사회의 평균 재임 기간은 각각 3.7 년과 8.5 년입니다.

주요 정보

Dave Mazzo

최고 경영자

US$1.4m

총 보상

CEO 급여 비율	48.0%
CEO 임기	9.6yrs
CEO 소유권	2.1%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30

CEO 보상 분석

Dave Mazzo 의 보수는 Lisata Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$1m	US$676k	-US$21m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	US$2m	US$650k	-US$54m
Sep 30 2022	n/a	n/a	-US$55m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$631k	-US$27m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$613k	-US$8m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$7m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$2m	US$597k	-US$19m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$2m	US$594k	-US$16m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$14m
Dec 31 2017	US$1m	US$577k	-US$16m

보상 대 시장: Dave 의 총 보상 ($USD 1.41M )은 US 시장( $USD 683.56K ).

보상과 수익: Dave 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dave Mazzo (67 yo)

9.6yrs

테뉴어

US$1,408,382

보상

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29,...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Mazzo	President	9.6yrs	US$1.41m	2.1% $ 510.3k
Kristen Buck	Executive VP of R&D and Chief Medical Officer	2.9yrs	US$969.82k	0.65% $ 157.8k
James Nisco	Senior VP of Finance	3.4yrs	데이터 없음	0.023% $ 5.5k
Tariq Imam	Vice President of Business Development & Operations and Corporate Counsel	1.6yrs	데이터 없음	데이터 없음
Gregory Berkin	Chief Information Officer	3.8yrs	데이터 없음	데이터 없음
John Menditto	Vice President of Investor Relations & Corporate Communications	6.7yrs	데이터 없음	데이터 없음
Gail Holler	Vice President of Human Resources	5.6yrs	데이터 없음	데이터 없음
William Sietsema	Vice President of Global Regulatory Affairs	no data	US$400.18k	데이터 없음

3.8yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: LSTA 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Mazzo	President	9.6yrs	US$1.41m	2.1% $ 510.3k
Steven Klosk	Independent Director	10.1yrs	US$120.00k	0.0052% $ 1.3k
Gregory Brown	Independent Chairman of the Board	7.8yrs	US$149.50k	0.0033% $ 805.3
Heidi Henson	Independent Director	1.9yrs	US$124.00k	0% $ 0
Gerald Nepom	Member of Type 1 Diabetes Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Negrin	Immune Modulation Program Advisor	no data	데이터 없음	데이터 없음
Robert Korngold	Immune Modulation Program Advisor	no data	데이터 없음	데이터 없음
David Horwitz	Immune Modulation Program Advisor	no data	데이터 없음	데이터 없음
David Peritt	Immune Modulation Program Advisor	no data	데이터 없음	데이터 없음
Noel Warner	Immune Modulation Program Advisor	no data	데이터 없음	데이터 없음
David Pearce	Member of Type 1 Diabetes Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kevan Herold	Member of Type 1 Diabetes Scientific Advisory Board	no data	데이터 없음	데이터 없음

8.7yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: LSTA 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.

Lisata Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Insufficient new directors

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

Recent updates

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Price target decreased to US$8.00

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Price target decreased to US$9.00

Consensus forecasts updated

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Price target decreased to US$8.67

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Analysts update estimates

Price target lowered to US$8.50

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

New 90-day high: US$2.89

Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius suspends CLBS119 COVID-19 study

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Price target raised to US$12.75

Caladrius Biosciences, Inc. Announces Executive Changes

New 90-day low: US$1.47

Caladrius Biosciences, Inc. Appoints Anne Whitaker to Board of Directors

Caladrius Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$1.59

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Insider recently bought US$100k worth of stock

New 90-day low - US$1.71

Caladrius Biosciences, Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO 보상 분석

CEO

테뉴어

보상